ATE280235T1 - Plasmid zur herstellung von crm-protein und diphtherie-toxin - Google Patents

Plasmid zur herstellung von crm-protein und diphtherie-toxin

Info

Publication number
ATE280235T1
ATE280235T1 AT94101770T AT94101770T ATE280235T1 AT E280235 T1 ATE280235 T1 AT E280235T1 AT 94101770 T AT94101770 T AT 94101770T AT 94101770 T AT94101770 T AT 94101770T AT E280235 T1 ATE280235 T1 AT E280235T1
Authority
AT
Austria
Prior art keywords
plasmid
diphtheria toxin
crm197
protein
novel
Prior art date
Application number
AT94101770T
Other languages
English (en)
Inventor
Benjamin J Metcalf
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE280235T1 publication Critical patent/ATE280235T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94101770T 1993-03-05 1994-02-07 Plasmid zur herstellung von crm-protein und diphtherie-toxin ATE280235T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2728393A 1993-03-05 1993-03-05

Publications (1)

Publication Number Publication Date
ATE280235T1 true ATE280235T1 (de) 2004-11-15

Family

ID=21836767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94101770T ATE280235T1 (de) 1993-03-05 1994-02-07 Plasmid zur herstellung von crm-protein und diphtherie-toxin

Country Status (21)

Country Link
US (1) US5614382A (de)
EP (1) EP0616034B1 (de)
JP (1) JP4144813B2 (de)
KR (1) KR100316004B1 (de)
CN (1) CN1100757A (de)
AT (1) ATE280235T1 (de)
AU (1) AU686126B2 (de)
BR (1) BR1100634A (de)
CA (1) CA2116914C (de)
CZ (1) CZ39394A3 (de)
DE (1) DE69434079T2 (de)
DK (1) DK0616034T3 (de)
ES (1) ES2231770T3 (de)
FI (1) FI112090B (de)
HU (1) HUT71320A (de)
IL (1) IL108822A (de)
NO (1) NO313758B1 (de)
NZ (1) NZ260027A (de)
PT (1) PT616034E (de)
SK (1) SK24094A3 (de)
ZA (1) ZA941548B (de)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69638145D1 (de) * 1995-04-14 2010-04-22 Us Gov Health & Human Serv Verfahren zur herbeiführung einer immuntoleranz mit hilfe von immuntoxinen
WO1998039363A2 (en) 1997-03-05 1998-09-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotoxins and methods of inducing immune tolerance
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US7125553B1 (en) 1996-04-15 2006-10-24 The United States of America as represented by the Department of Health and Human Services c/o Centers for Disease Control and Prevention Methods of inducing immune tolerance using immunotoxins
CA2283497A1 (en) * 1997-03-05 1998-09-11 David M. Neville Vectors and methods for expression of mutant proteins
US6676943B1 (en) 1997-04-24 2004-01-13 Regents Of The University Of Minnesota Human complement C3-degrading protein from Streptococcus pneumoniae
CN1086945C (zh) * 1997-06-03 2002-07-03 胡章英 白喉口服液
GB9923060D0 (en) * 1999-09-29 1999-12-01 Chiron Spa Vaccine
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
MY144231A (en) 2003-12-17 2011-08-15 Wyeth Corp Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
KR101157694B1 (ko) 2003-12-17 2012-06-20 와이어쓰 엘엘씨 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN113198012B (zh) 2005-04-08 2024-09-17 惠氏有限责任公司 多价肺炎球菌多糖－蛋白质缀合物组合物
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
ATE552839T1 (de) 2006-05-31 2012-04-15 Baroncini Luciana Pharmazeutische verwendung von immunologisch mit diphtherie-toxin korrelierten proteinmolekülen
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CN101265288B (zh) * 2007-03-13 2012-03-21 齐鲁制药有限公司 Crm197突变体的纯化方法
EP2424562B1 (de) 2009-04-30 2015-10-07 Coley Pharmaceutical Group, Inc. Pneumokokken-vakzine und deren verwendung
BRPI1011753B8 (pt) 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
MX343111B (es) 2009-06-22 2016-10-25 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus.
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
MX343356B (es) 2010-03-30 2016-11-03 Pfenex Inc * Toxinas proteicas recombinantes de alto nivel de expresion.
AU2010201410B2 (en) * 2010-03-30 2015-04-30 Pelican Technology Holdings, Inc. High level expression of recombinant CRM197
RU2607024C2 (ru) 2010-06-04 2017-01-10 УАЙТ ЭлЭлСи Вакцины streptococcus pneumoniae
EP2942061A3 (de) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige-ch3-peptidimpfstoff
PL3246044T5 (pl) 2010-08-23 2024-06-17 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
US9512185B2 (en) 2011-06-01 2016-12-06 Xiamen University Fusion protein comprising diphtheria toxin non-toxic mutant CRM197 or fragment thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP4043029A1 (de) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis-zusammensetzungen und verfahren dafür
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
WO2014013375A1 (en) 2012-07-16 2014-01-23 Pfizer Inc. Saccharides and uses thereof
CN102766647A (zh) * 2012-07-25 2012-11-07 天津康希诺生物技术有限公司 在白喉杆菌中稳定复制的表达载体及含该载体的白喉杆菌
PL2885007T3 (pl) 2012-08-16 2019-02-28 Pfizer Inc. Sposoby glikokoniugacji i kompozycje
MX2015002483A (es) 2012-10-03 2016-01-08 Glaxosmithkline Biolog Sa Composiciones inmunogenicas.
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR101787217B1 (ko) 2012-12-20 2017-10-18 화이자 인코포레이티드 당접합 방법
US10517936B2 (en) 2013-01-04 2019-12-31 OBI Pharma., Inc. Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN104140972B (zh) * 2013-05-07 2018-01-23 上海惠盾生物技术有限公司 白喉毒素突变体crm197的制备方法
US9908805B2 (en) 2013-08-26 2018-03-06 Corning Incorporated Method for localized annealing of chemically strengthened glass
EP3041502A2 (de) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis-zusammensetzungen und verfahren dafür
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
SI3583947T1 (sl) 2014-01-21 2024-01-31 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
EP3096783B1 (de) 2014-01-21 2021-07-07 Pfizer Inc. Kapsulare polysaccharide aus streptococcus pneumoniae und konjugate davon
KR102157200B1 (ko) 2014-01-21 2020-09-21 화이자 인코포레이티드 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
EP3099800B1 (de) 2014-01-31 2020-10-14 Fina Biosolutions LLC Expression und reinigung von crm197 und verwandten proteinen
ES2930318T3 (es) 2014-02-14 2022-12-09 Pfizer Conjugados glucoproteicos inmunogénicos
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EA035117B1 (ru) 2014-11-20 2020-04-29 Байолоджикал И Лимитед Кодон-оптимизированный полинуклеотид для экспрессии crmна высоком уровне
IL252915B2 (en) 2015-01-15 2024-04-01 Pfizer Immunogenic compositions for use in pneumococcal vaccines
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3292146A1 (de) 2015-05-04 2018-03-14 Pfizer Inc Gruppe-b-streptococcus-polysaccharid-proteinkonjugate, verfahren zur herstellung von konjugaten, immunogene zusammensetzungen mit konjugaten und verwendungen davon
MX389480B (es) 2015-06-23 2025-03-20 Biological E Ltd Vacuna conjugada neumococica polivalente.
IL303998A (en) 2015-07-21 2023-08-01 Pfizer Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
US11965009B2 (en) 2016-03-10 2024-04-23 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
MX2018010850A (es) 2016-03-10 2019-05-15 Univ Johns Hopkins Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos.
US11203626B2 (en) 2016-03-10 2021-12-21 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
EP3269385A1 (de) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
US11191822B2 (en) 2016-06-22 2021-12-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
BR112019001995A2 (pt) 2016-08-05 2019-05-07 Sanofi Pasteur, Inc. composição de conjugado de polissacarídeo pneumocócico multivalente ? proteína
IL264552B2 (en) 2016-08-05 2023-04-01 Sanofi Pasteur Inc A multivalent pneumococcal protein-polysaccharide conjugate preparation
EP3518965A1 (de) 2016-09-30 2019-08-07 Biological E Limited Mehrwertige pneumokokken-impfstoffzusammensetzungen mit polysaccharidproteinkonjugaten
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US11998599B2 (en) 2016-12-30 2024-06-04 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
RU2762723C2 (ru) 2017-01-20 2021-12-22 Пфайзер Инк. Иммуногенные композиции для применения в пневмококковых вакцинах
CN110225757A (zh) 2017-01-31 2019-09-10 默沙东公司 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
JP7010961B2 (ja) 2017-01-31 2022-02-10 ファイザー・インク 髄膜炎菌組成物およびその方法
CN110225764A (zh) 2017-01-31 2019-09-10 默沙东公司 制备多糖-蛋白缀合物的方法
KR101908590B1 (ko) 2017-02-01 2018-10-16 (주)포바이오코리아 Crm197의 용해성 단백질 발현 및 정제 방법
US11246918B2 (en) 2017-02-03 2022-02-15 Eva Barbara Schadeck Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
EP3585803B1 (de) 2017-02-24 2025-09-24 Merck Sharp & Dohme LLC Pneumokokkenkonjugatimpfstoffformulierungen
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
JP7161493B2 (ja) * 2017-04-22 2022-10-26 バイオロジカル イー リミテッド Ｃｒｍ１９７の高レベル製造のための改良法
RS65893B1 (sr) 2017-09-07 2024-09-30 Merck Sharp & Dohme Llc Pneumokokni polisaharidi i njihova primena u imunogenim konjugatima polisaharid-proteinski nosač
UA128603C2 (uk) 2017-12-06 2024-08-28 Мерк Шарп Енд Доум Елелсі Полівалентна імуногенна композиція проти пневмококового захворювання
KR102812816B1 (ko) 2018-02-05 2025-05-27 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
KR102475419B1 (ko) * 2018-07-16 2022-12-07 주식회사 유바이오로직스 Crm197을 고농도로 발현하는 코리네박테리움 균주
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2021003358A (es) 2018-09-23 2021-05-27 Biological E Ltd Polisacaridos capsulares purificados de streptococcus pneumoniae.
CN109100517A (zh) * 2018-10-08 2018-12-28 武汉生命科技股份有限公司 一种用于检测白喉抗体的抗原蛋白、试剂盒及制备方法
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
SG11202106541WA (en) 2018-12-19 2021-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
AU2020323498A1 (en) 2019-07-31 2022-03-03 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
KR102871663B1 (ko) 2019-09-27 2025-10-16 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
US20230000966A1 (en) 2019-11-01 2023-01-05 Pfizer Inc. Escherichia coli compositions and methods thereof
BR112022015796A2 (pt) 2020-02-21 2022-10-11 Pfizer Purificação de sacarídeos
CN115605498A (zh) 2020-02-23 2023-01-13 辉瑞公司（Us） 大肠杆菌组合物及其方法
EP3900739A1 (de) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
EP3919076A1 (de) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische oligosaccharidimpfstoffe gegen streptococcus pneumoniae mit mikropartikel-adjuvans-formulierungen
WO2022043855A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
PE20231385A1 (es) 2020-09-17 2023-09-12 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas
EP4232593A1 (de) 2020-10-22 2023-08-30 Pfizer Inc. Verfahren zur reinigung von bakteriellen polysacchariden
TW202227467A (zh) 2020-10-27 2022-07-16 美商輝瑞大藥廠 大腸桿菌組合物及其方法
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
KR20220102871A (ko) 2021-01-14 2022-07-21 (주)셀트리온 다가 폐렴구균 다당류-단백질 접합체를 포함하는 면역원성 조성물
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
JP2024517780A (ja) 2021-05-03 2024-04-23 ファイザー・インク 細菌およびベータコロナウイルス感染症に対するワクチン接種
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PH12023553205A1 (en) 2021-05-28 2024-02-19 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
CN116942804A (zh) 2022-04-19 2023-10-27 上海瑞宙生物科技有限公司 多价肺炎球菌多糖结合疫苗的成分及其应用
KR20250008122A (ko) 2022-05-11 2025-01-14 화이자 인코포레이티드 보존제를 갖는 백신 제형의 제조 방법
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
TW202432182A (zh) 2022-10-24 2024-08-16 瑞士商愛杜西亞製藥有限公司 對抗克雷伯氏肺炎桿菌之疫苗
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
KR20250107930A (ko) 2022-11-22 2025-07-14 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
KR20250113501A (ko) 2022-12-01 2025-07-25 화이자 인코포레이티드 폐렴구균 접합체 백신 제형
AU2023389141A1 (en) 2022-12-08 2025-07-17 Idorsia Pharmaceuticals Ltd Vaccine against klebsiella pneumoniae
EP4661911A1 (de) 2023-02-10 2025-12-17 Pfizer Inc. Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon
CN121038808A (zh) 2023-03-30 2025-11-28 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其用途
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024238731A1 (en) 2023-05-18 2024-11-21 Merck Sharp & Dohme Llc Compounds and adjuvant formulations useful in pneumococcal vaccines
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
US20250161420A1 (en) 2023-11-16 2025-05-22 Merck Sharp & Dohme Llc Peptide conjugate vaccine compositions and methods for the treatment of alzheimer's disease
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
TW202532099A (zh) 2024-02-14 2025-08-16 美商默沙東有限責任公司 肺炎鏈球菌結合物疫苗及其使用方法
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH660375A5 (it) * 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
FR2549855B1 (fr) * 1983-07-29 1987-03-27 Grp Genie Genetique Sequence nucleotidique codant pour le peptide signal de la toxine diphterique, vecteur contenant cette sequence nucleotidique, leur application a la transformation de micro-organismes et compositions peptidiques obtenues

Also Published As

Publication number Publication date
BR1100634A (pt) 1999-12-07
EP0616034A2 (de) 1994-09-21
CN1100757A (zh) 1995-03-29
NO940774L (no) 1994-09-06
HU9400657D0 (en) 1994-05-30
DK0616034T3 (da) 2005-02-21
IL108822A (en) 2004-09-27
FI941050L (fi) 1994-09-06
CA2116914A1 (en) 1994-09-06
IL108822A0 (en) 1994-06-24
PT616034E (pt) 2005-02-28
EP0616034A3 (en) 1996-10-16
FI112090B (fi) 2003-10-31
FI941050A0 (fi) 1994-03-04
DE69434079T2 (de) 2005-02-24
SK24094A3 (en) 1995-03-08
AU5759594A (en) 1994-09-08
JPH06292593A (ja) 1994-10-21
JP4144813B2 (ja) 2008-09-03
DE69434079D1 (de) 2004-11-25
ES2231770T3 (es) 2005-05-16
CA2116914C (en) 2005-02-08
NO940774D0 (no) 1994-03-04
KR100316004B1 (ko) 2002-02-19
HUT71320A (en) 1995-11-28
NZ260027A (en) 1996-03-26
ZA941548B (en) 1994-10-03
EP0616034B1 (de) 2004-10-20
AU686126B2 (en) 1998-02-05
NO313758B1 (no) 2002-11-25
KR940021731A (ko) 1994-10-19
CZ39394A3 (en) 1995-02-15
US5614382A (en) 1997-03-25

Similar Documents

Publication Publication Date Title
ATE280235T1 (de) Plasmid zur herstellung von crm-protein und diphtherie-toxin
EG19101A (en) Process for preparing of expression of human proapolipoprotein A.1.
RU2003128977A (ru) Способы секреторной продукции белков
DE88166T1 (de) Verfahren zum exprimieren eines gens.
IL103057A0 (en) Dna sequences encoding gelonin polypeptide
EP0769551A4 (de) Für die erhöhung der carotenoidensbeute nützliches dna-strang
ATE113982T1 (de) Verzweigungsenzym und dessen verwendung.
DE68926893D1 (de) Verfahren zur Herstellung von clavulanic Säure
AU3475495A (en) Process for producing recombinant proteins, plasmids and modified cells
DE69224269D1 (de) Biosynthetisches Verfahren zur Herstellung von Protein
DE69535126D1 (de) Verfahren zur herstellung von sekundären metaboliten
ATE111528T1 (de) Optimierte fermentationsverfahren zur herstellung von fremdproteinen in e.coli.
CA2121481A1 (en) Expression of polypeptides in e.coli under control of the e.coli mdh-gene promoter
RU94007083A (ru) Способ получения дифтерийного токсина или белка crm, плазмиды, микроорганизма
ATE190653T1 (de) Verfahren zur herstellung von rekombinanten und synthetischen peptiden und deren verwendung
DE69737007D1 (de) Protein-disulfidisomerase-Gen eines methylotrophen Hefestammes
KR970021294A (ko) 유기산 생성이 억제된 대장균 변이주

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0616034

Country of ref document: EP

REN Ceased due to non-payment of the annual fee